GOLDILOX
A Phase IIB, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction, Persistent Inflammation, and Elevated N-terminal Prohormone Brain Natriuretic Peptide
- Stage
- klaar
- Medicine
- MEDI6570
- Population
- ASCVD
- Phase
- IIB
- First Patient In
- 19 January 2022
- Last Patient In
- 23 December 2022
- Last Patient Last Visit
- 11 November 2023
National Lead
dr. mr. A.J.M. Oude Ophuis
Cardioloog
Office Contact
